

In re: Patent Application of YOKOI et al  
Serial No. 09/680,514

---

Claims 1-9 (Canceled).

D 10. (Currently Amended) A fusion polypeptide which comprises a human granulocyte colony stimulating factor polypeptide and c-mpl ligand polypeptide and has no mouse IL-3 activity as measured by inability to stimulate growth of Ba/F3 cells, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence in which the amino acid nos. 155 to 3278 of the amino acid sequence shown in SEQ ID NO:1 is replaced by an amino acid sequence selected from an amino acid sequence represented in Table 1 and Table 2 a) to j) and l).

11. (Currently Amended) A fusion polypeptide which comprises a human granulocyte colony stimulating factor polypeptide and c-mpl ligand polypeptide and has no mouse IL-3 activity as measured by inability to stimulate growth of Ba/F3 cells, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO:1 or an amino acid sequence in which the amino acid nos. 155 to 3278 of the amino acid sequence shown in SEQ ID NO:1 is replaced by an amino acid sequence selected from an amino acid sequence represented in Table 1 and Table 2 a) to j) and l), and the human granulocyte

721759

In re: Patent Application of YOKOI et al  
Serial No. 09/680,514

colony stimulating factor polypeptide is fused via a spacer peptide to the c-mpl ligand polypeptide.

12. (Previously Amended) The fusion polypeptide according to claim 11, wherein the polypeptide is selected from a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2 or SEQ ID NO:3, an amino acid sequence in which the amino acid nos. 167 to 340 of the amino acid sequence shown in SEQ ID NO:2 is replaced by an amino acid sequence selected from the amino acid sequences represented in Table 1 and Table 2 a) to j) and l), and an amino acid sequence in which the amino acid nos. 171 to 344 of the amino acid sequence shown in SEQ ID NO: 3 is replaced by an amino acid sequence selected from the amino acid sequences represented in Table 1 and Table 2 a) to j) and l).

13. (Previously Added) The fusion polypeptide of claim 10 chemically modified with a polyalkylene glycol derivative.

14. (Previously Added) The fusion polypeptide according to claim 13 wherein the polyalkylene glycol derivative is a polyethylene glycol derivative, a polypropylene glycol derivative or a polyoxyethylene-polyoxypropylene copolymer derivative.

721759

In re: Patent Application of YOKOI et al  
Serial No. 09/680,514

15. (Previously Added) A pharmaceutical composition for treating anemia comprising the fusion polypeptide of claim 10 in a pharmaceutically acceptable carrier, vehicle or auxiliary agent.

16. (Previously Added) A method of treating anemia comprising administering to a subject in need of same an effective amount of the fusion polypeptide of claim 10.

DI  
Cont  
17. (Previously Added) A method of simultaneously amplifying platelets and neutrophils comprising administering to a subject in need of same an effective amount of the fusion polypeptide of claim 10.

18. (Previously Added) A method of controlling formation of megakaryocyte colonies and neutrophil colonies and/or controlling differentiation or maturation of megakaryocyte precursors and neutrophil precursors comprising administering to a subject in need of same an effective amount of the fusion polypeptide of claim 10.

721759